shuigui56
Lv1
50 积分
2023-02-23 加入
-
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
24天前
已完结
-
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
25天前
已完结
-
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
27天前
已完结
-
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
28天前
已完结
-
Effect of early versus late or no tracheostomy on mortality and pneumonia of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis
28天前
已完结
-
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
1个月前
已完结
-
The oral microbiome: diversity, biogeography and human health
3个月前
已完结
-
Melanoma and microbiota: Current understanding and future directions
3个月前
已完结
-
Microsatellite Instability in Colorectal Cancer
4个月前
已完结
-
Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality
4个月前
已完结